Scientech Research LLC Acquires New Shares in Insmed Incorporated (NASDAQ:INSM)

Scientech Research LLC bought a new position in shares of Insmed Incorporated (NASDAQ:INSM) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 20,170 shares of the biopharmaceutical company’s stock, valued at approximately $1,351,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC grew its holdings in shares of Insmed by 8.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 135 shares during the period. CWM LLC boosted its stake in Insmed by 11.0% during the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 155 shares during the period. First Horizon Advisors Inc. increased its position in shares of Insmed by 83.4% during the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 287 shares during the last quarter. Beacon Financial Advisory LLC raised its stake in shares of Insmed by 4.6% in the 2nd quarter. Beacon Financial Advisory LLC now owns 13,825 shares of the biopharmaceutical company’s stock valued at $926,000 after acquiring an additional 605 shares during the period. Finally, State Board of Administration of Florida Retirement System lifted its holdings in shares of Insmed by 1.6% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 38,232 shares of the biopharmaceutical company’s stock worth $1,037,000 after acquiring an additional 610 shares during the last quarter.

Insider Activity at Insmed

In related news, insider Martina M.D. Flammer sold 13,436 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total value of $1,006,625.12. Following the completion of the sale, the insider now directly owns 106,134 shares of the company’s stock, valued at $7,951,559.28. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, insider Michael Alexander Smith sold 27,871 shares of the company’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $74.35, for a total value of $2,072,208.85. Following the completion of the sale, the insider now owns 67,856 shares in the company, valued at approximately $5,045,093.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Martina M.D. Flammer sold 13,436 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the sale, the insider now owns 106,134 shares of the company’s stock, valued at approximately $7,951,559.28. The disclosure for this sale can be found here. Insiders have sold 78,882 shares of company stock valued at $5,765,446 in the last ninety days. Insiders own 4.60% of the company’s stock.

Insmed Stock Performance

NASDAQ:INSM opened at $72.48 on Friday. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53. The company has a debt-to-equity ratio of 25.05, a current ratio of 2.71 and a quick ratio of 2.53. The firm has a market capitalization of $10.77 billion, a PE ratio of -13.86 and a beta of 1.11. The business’s fifty day moving average price is $74.36 and its 200 day moving average price is $53.11.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.72). The firm had revenue of $90.34 million during the quarter, compared to analyst estimates of $87.95 million. The business’s revenue was up 17.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.78) EPS. On average, sell-side analysts anticipate that Insmed Incorporated will post -5.42 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on INSM. The Goldman Sachs Group lifted their target price on shares of Insmed from $74.00 to $102.00 and gave the company a “buy” rating in a report on Wednesday, July 10th. Evercore ISI lifted their price objective on Insmed from $42.00 to $75.00 and gave the company an “outperform” rating in a research note on Friday, June 21st. StockNews.com lowered Insmed from a “hold” rating to a “sell” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. lifted their target price on Insmed from $55.00 to $72.00 and gave the company an “overweight” rating in a research report on Thursday, June 20th. Finally, Stifel Nicolaus increased their price target on shares of Insmed from $74.00 to $88.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, Insmed has an average rating of “Moderate Buy” and a consensus target price of $81.40.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.